Steven Averbuch has joined Caris Life Sciences' scientific advisory board. Averbuch recently retired from the role of vice president and head of precision medicine in the translational medicine division of R&D at Bristol-Myers Squibb. During his tenure, Averbuch spearheaded the Pharmacodiagnostics Center of Excellence, which led to the application of BMS' precision medicine strategy across all therapeutic areas. Prior to this, Averbuch oversaw corporate-wide strategic initiatives for translational and targeted medicine at BMS. He also served as head of early global clinical research at the company. Averbuch also previously held leadership roles with Merck Research Laboratories and AstraZeneca, and held academic appointments at Mount Sinai School of Medicine and the US Public Health Service School of Medicine.